I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
GRADE evidence profiles:
Banghyun Lee
;
Suk-Joon Chang
;
Byung Su Kwon
...
doi:10.1371/journal.pone.0294647.s004. , 2023
Link:
https://doi.org/10.1371/journal.pone.0294647.s004
RT Journal T1
GRADE evidence profiles
UL https://suche.suub.uni-bremen.de/peid=base-ftdeakinunifig:oai:figshare.com:article_24583572&Exemplar=1&LAN=DE A1 Banghyun Lee A1 Suk-Joon Chang A1 Byung Su Kwon A1 Joo-Hyuk Son A1 Myong Cheol Lim A1 Yun Hwan Kim A1 Shin-Wha Lee A1 Chel Hun Choi A1 Kyung Jin Eoh A1 Jung-Yun Lee A1 Dong Hoon Suh A1 Yong Beom Kim YR 2023 K1 Biochemistry K1 Medicine K1 Cell Biology K1 Genetics K1 Immunology K1 Cancer K1 Science Policy K1 Infectious Diseases K1 serious adverse events K1 bevacizumab maintenance therapy K1 parpi treatment regardless K1 parpi maintenance therapy K1 hrd without brcam K1 hr ] K1 0 K1 ci ] K1 year overall survival K1 significantly better two K1 significantly better five K1 placebo group ) K1 analysis </ p K1 maintenance therapy K1 significantly better K1 parpi treatment K1 parpi group K1 hrd ) K1 placebo group K1 74 ) K1 68 ) K1 year progression K1 xlink "> K1 two groups K1 systematically evaluate K1 survival outcomes K1 recombination proficiency K1 recombination deficiency K1 polymerase inhibitor K1 hazard ratio K1 grade 3 K1 free survival K1 confidence interval K1 227 studies K1 2 </ JF doi:10.1371/journal.pone.0294647.s004 LK http://dx.doi.org/https://doi.org/10.1371/journal.pone.0294647.s004 DO https://doi.org/10.1371/journal.pone.0294647.s004 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)